Board of Directors of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd.
Special Opinion on the Self-Inspection of Independent Directors' Independence for 2025
In accordance with the "Administrative Measures for Independent Directors of Listed Companies," the "Shenzhen Stock Exchange Stock Listing Rules," and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guidelines No. 1 - Normative Operation of the Main Board Listed Companies," etc., the Board of Directors of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), in conjunction with the "Report on the Self-Inspection of Independence by Independent Directors" issued by the incumbent independent directors for 2025, has evaluated their independence and hereby issues the following special opinion:
For 2025, the incumbent independent directors, Lv Haizhou, Liu Yuehui, and Cai Min, do not hold any positions in the Company other than independent director and member of the Board's special committees. They also do not hold any positions in the Company's principal shareholders. There are no relationships of interest or other relationships that may hinder their independent and objective judgment with the Company and its principal shareholders. There are no circumstances that affect the independence of the independent directors, which complies with the requirements of relevant laws and regulations such as the "Administrative Measures for Independent Directors of Listed Companies," the "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guidelines No. 1 - Normative Operation of the Main Board Listed Companies," and the "Articles of Association" regarding the independence of independent directors.